Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+41-61-3241111
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Novartis (VTX:NOVN) Frequently Asked Questions
What is Novartis' stock symbol?
Novartis trades on the VTX under the ticker symbol "NOVN."
What price target have analysts set for NOVN?
19 analysts have issued 1 year target prices for Novartis' stock. Their forecasts range from CHF 75 to CHF 110. On average, they anticipate Novartis' stock price to reach CHF 91.53 in the next twelve months. View Analyst Price Targets for Novartis.
What is the consensus analysts' recommendation for Novartis?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.
Has Novartis been receiving favorable news coverage?
Media headlines about NOVN stock have been trending somewhat negative on Thursday, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novartis earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Novartis' key competitors?
Some companies that are related to Novartis include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), AquaBounty Technologies (AQB), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF), Cardiome Pharma (COM), China Longyi Group Int'l (CGYG) and Creative Medical Technology (CELZ).
What other stocks do shareholders of Novartis own?
Who are Novartis' key executives?
Novartis' management team includes the folowing people:
- Mr. G. Kelly Martin, CEO & Director (Age 59)
- Dr. Nathan Stasko, Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)
- Mr. Jeff N. Hunter, Exec. VP, Chief Bus. Officer & Company Sec. (Age 61)
- Ms. Paula Brown Stafford, Chief Devel. Officer & Director (Age 53)
- Mr. Andrew Novak, VP & Chief Accounting Officer
What is Novartis' official website?
How can I contact Novartis?
Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111.
MarketBeat Community Rating for Novartis (VTX NOVN)
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
